View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsChemoCentryx 将来の成長Future 基準チェック /56主要情報69.1%収益成長率91.90%EPS成長率Biotechs 収益成長22.9%収益成長率85.1%将来の株主資本利益率6.59%アナリストカバレッジLow最終更新日n/a今後の成長に関する最新情報Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 8 analysts covering ChemoCentryx expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$157.3m in 2024. Average annual earnings growth of 57% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesReported Earnings • Aug 09Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.56 loss in 2Q 2021)Second quarter 2022 results: US$0.44 loss per share (up from US$0.56 loss in 2Q 2021). Revenue: US$11.8m (up US$9.95m from 2Q 2021). Net loss: US$31.7m (loss narrowed 19% from 2Q 2021). Over the next year, revenue is forecast to grow 264%, compared to a 24% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 102% per year, which means it is well ahead of earnings.Reported Earnings • May 06First quarter 2022 earnings released: US$0.55 loss per share (vs US$0.43 loss in 1Q 2021)First quarter 2022 results: US$0.55 loss per share (down from US$0.43 loss in 1Q 2021). Revenue: US$5.46m (down 47% from 1Q 2021). Net loss: US$38.6m (loss widened 30% from 1Q 2021). Over the next year, revenue is forecast to grow 317%, compared to a 28% growth forecast for the industry in Germany.Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Executive VP, Chief Financial & Administrative Officer, Secretary and Director Susan Kanaya was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Apr 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Executive VP, Chief Financial & Administrative Officer, Secretary and Director Susan Kanaya was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 03Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: US$1.89 loss per share (down from US$0.84 loss in FY 2020). Revenue: US$32.2m (down 50% from FY 2020). Net loss: US$131.8m (loss widened 138% from FY 2020). Revenue missed analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 189%, compared to a 64% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 8 analysts covering ChemoCentryx expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$157.3m in 2024. Average annual earnings growth of 57% is required to achieve expected profit on schedule.Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.35 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$17.7m (up 249% from 3Q 2020). Net loss: US$22.3m (loss narrowed 7.3% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 62% per year, which means it is well ahead of earnings.Reported Earnings • Aug 11Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.32 profit in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: US$1.81m (down 96% from 2Q 2020). Net loss: US$39.2m (down 294% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.Recent Insider Transactions • May 11Executive VP & COO recently bought €99k worth of stockOn the 7th of May, Tausif Butt bought around 11k shares on-market at roughly €9.10 per share. This was the largest purchase by an insider in the last 3 months. This was Tausif's only on-market trade for the last 12 months.Reported Earnings • May 02First quarter 2021 earnings released: US$0.43 loss per share (vs US$0.35 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$10.4m (up 72% from 1Q 2020). Net loss: US$29.7m (loss widened 37% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 59% per year, which means it is well ahead of earnings.Recent Insider Transactions • Mar 13Director recently sold €1.5m worth of stockOn the 5th of March, Geoffrey Parker sold around 32k shares on-market at roughly €47.52 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €4.8m more than they bought in the last 12 months.Reported Earnings • Mar 02Full year 2020 earnings released: US$0.84 loss per share (vs US$0.97 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses were not reduced. Full year 2020 results: Revenue: US$64.9m (up 80% from FY 2019). Net loss: US$55.4m (flat on FY 2019). Over the last 3 years on average, earnings per share has fallen by 65% per year but the company’s share price has increased by 86% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Mar 02Revenue misses expectationsRevenue missed analyst estimates by 5.6%. Over the next year, revenue is expected to shrink by 19% compared to a 55% growth forecast for the Biotechs industry in Germany.Is New 90 Day High Low • Feb 06New 90-day high: €54.18The company is up 20% from its price of €45.32 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €86.28 per share.Recent Insider Transactions • Feb 05Independent Director recently sold €1.0m worth of stockOn the 2nd of February, Thomas Edwards sold around 20k shares on-market at roughly €50.67 per share. In the last 3 months, they made an even bigger sale worth €1.3m. Insiders have been net sellers, collectively disposing of €3.3m more than they bought in the last 12 months.Recent Insider Transactions • Dec 30Independent Director recently sold €1.3m worth of stockOn the 28th of December, Thomas Edwards sold around 25k shares on-market at roughly €50.19 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.3m more than they bought in the last 12 months.Is New 90 Day High Low • Dec 15New 90-day high: €49.12The company is up 12% from its price of €43.92 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €76.07 per share.Is New 90 Day High Low • Dec 10New 90-day high: €47.85The company is up 12% from its price of €42.71 on 03 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €70.28 per share.Is New 90 Day High Low • Nov 20New 90-day high: €47.06The company is up 4.0% from its price of €45.15 on 21 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €68.44 per share.Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.35 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$5.09m (down 52% from 3Q 2019). Net loss: US$24.1m (loss widened 87% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 96% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Nov 11Revenue misses expectationsRevenue missed analyst estimates by 53%. Over the next year, revenue is expected to shrink by 6.9% compared to a 309% growth forecast for the Biotechs industry in Germany.お知らせ • Oct 29ChemoCentryx, Inc. Announces Positive Topline Results of Phase II Aurora Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)ChemoCentryx, Inc. announced positive topline data from the company’s AURORA randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial of avacopan for the treatment of the chronic disabling skin disease Hidradenitis Suppurativa (HS). Avacopan is a first-in-class, orally-administered selective inhibitor of the complement C5a receptor. The Phase II AURORA clinical trial randomized 398 patients to one of three treatment arms. The study population included patients with moderate HS (Hurley Stage II) or severe HS (Hurley Stage III), which were stratified evenly across the treatment groups. The primary endpoint of the proportion of all patients (both moderate Hurley Stage II plus severe Hurley Stage III) achieving Hidradenitis Suppurativa Clinical Response (HiSCR), as assessed 10 mg twice-daily (BID) and 30 mg BID dosing regimens of avacopan against placebo after 12 weeks of treatment in the combined study population, was not achieved with statistical significance at either dose level, although a numerical improvement was noted at the 30mg BID dose. Importantly, avacopan 30mg BID demonstrated a statistically significant higher response than placebo in the pre-specified population of Hurley Stage III (severe) HS patients in the study. The Company plans to advance avacopan into Phase III development for the treatment of severe HS. A consistency of effect with avacopan was noted in Hurley Stage III patients across every secondary endpoint assessed to date. Favorable reductions for avacopan were observed in International HS Severity Score (IHS4), as well as reduction in AN (abscesses and inflammatory nodules), draining fistula, and abscess count at week 12 (all % change from baseline to week 12), relative to placebo. Avacopan demonstrated a favorable safety profile. Treatment emergent adverse events (TEAEs) of all types were observed to be fewer in the avacopan groups (48.5%) than with placebo (55%). The majority of TEAEs were related to underlying HS and were mild to moderate. Serious TEAEs were observed in 2.3% of placebo patients vs. 1.5% on avacopan.お知らせ • Sep 18ChemoCentryx, Inc. Announces FDA Acceptance of the Avacopan New Drug Application for the Treatment of ANCA-Associated VasculitisChemoCentryx, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for avacopan, an orally-administered selective complement 5a receptor inhibitor, for the treatment of ANCA-Associated Vasculitis and has set July 7, 2021 as the Prescription Drug User Fee Act (PDUFA) goal date for the avacopan NDA. Avacopan is a first-in-class, orally administered therapy that employs a novel, highly targeted mode of action in the treatment of ANCA-associated vasculitis. In its NDA acceptance letter, the FDA also indicated that it may, but has not yet determined whether to hold an advisory committee meeting to discuss the application per guidelines for new molecular entities. The NDA included data from the global, Phase III ADVOCATE trial, which demonstrated statistical superiority in sustaining remission at 52 weeks in the avacopan group compared to the prednisone group. In the trial, the avacopan group also showed significantly lower glucocorticoid toxicity, greater improvement in kidney function and greater improvement in health-related quality of life measures compared to the prednisone group. Finally, avacopan demonstrated favorable safety results, with fewer patients having serious adverse events in the avacopan group than in the prednisone group. ADVOCATE and ANCA-Associated Vasculitis: The ADVOCATE trial of avacopan was a global, randomized, double-blind, active-controlled, double-dummy Phase III trial of 331 patients with ANCA-associated vasculitis in 20 countries. Eligible study subjects were randomized to receive avacopan plus either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate) or prednisone plus either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate). ANCA-associated vasculitis is a systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. This results in organ damage and failure, with the kidney as the major target, and is fatal if not treated. Currently, treatment for ANCA-associated vasculitis consists of courses of non-specific immuno-suppressants (cyclophosphamide or rituximab), combined with the administration of daily glucocorticoids (steroids) for prolonged periods of time, which can be associated with significant clinical risk including death from infection. Avacopan is a first-in-class, orally-administered small molecule that employs a novel, highly targeted mode of action in the treatment of ANCA-associated vasculitis and other complement-driven autoimmune and inflammatory diseases. By precisely blocking the receptor (the C5aR) for the pro-inflammatory complement system fragment known as C5a on destructive inflammatory cells such as blood neutrophils, avacopan arrests the ability of those cells to do damage in response to C5a activation, which is known to be the driver of ANCA-associated vasculitis. Current therapies for ANCA-associated vasculitis and other related illnesses typically include broad immunosuppression with daily doses of glucocorticoids (steroids) such as prednisone or methylprednisone, which can cause significant illness and even death. Avacopan therapy was designed to prevent these outcomes. Moreover, avacopan’s selective inhibition of only the C5aR leaves the beneficial C5a pathway through the C5L2 receptor functioning normally. ChemoCentryx is also developing avacopan for the treatment of patients with C3 glomerulopathy (C3G) and hidradenitis suppurativa (HS). The U.S. Food and Drug Administration has granted avacopan orphan drug designation for ANCA-associated vasculitis and C3G. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of ANCA-associated vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), as well as for C3G. ChemoCentryx is responsible for the discovery and development of avacopan and owns and retains the commercial rights to the drug in the United States. ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan in markets outside of the U.S.お知らせ • Aug 04ChemoCentryx, Inc. to Report Q2, 2020 Results on Aug 10, 2020ChemoCentryx, Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 10, 2020お知らせ • Jul 03ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from Russell Microcap IndexChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from Russell Microcap Index業績と収益の成長予測DB:2CX - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202441968-6116112/31/2023190-55-25-12212/31/202264-140-94-5226/30/202237-133-59-53N/A3/31/202227-141-54-45N/A12/31/202132-132-95-76N/A9/30/202134-121-112-84N/A6/30/202122-123-102-75N/A3/31/202169-63-101-75N/A12/31/202065-55-97-81N/A9/30/202071-41-89-82N/A6/30/202076-30-85-83N/A3/31/202034-65-81-79N/A12/31/201936-55-71-70N/A9/30/201935-51-66-65N/A6/30/201934-49-66-66N/A3/31/201942-40-44-43N/A12/31/201843-381616N/A9/30/201890123638N/A6/30/201890174142N/A3/31/201884141920N/A12/31/2017821845N/A9/30/201731-29-10-10N/A6/30/201726-30-5-5N/A3/31/201720-317676N/A12/31/201612-403939N/A9/30/20167-443839N/A6/30/20163-483838N/A3/31/2016N/A-51N/A-41N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 2CXは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 0.03% ) よりも高い成長率であると考えられます。収益対市場: 2CX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: 2CX今後 3 年以内に収益を上げることが予想されます。収益対市場: 2CXの収益 ( 85.1% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: 2CXの収益 ( 85.1% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 2CXの 自己資本利益率 は、3年後には低くなると予測されています ( 6.6 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/10/23 14:17終値2022/10/19 00:00収益2022/06/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ChemoCentryx, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15 アナリスト機関Madhu KumarB. Riley Securities, Inc.Harshita PolishettyB. Riley Securities, Inc.Dae Gon HaBTIG12 その他のアナリストを表示
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 8 analysts covering ChemoCentryx expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$157.3m in 2024. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
Reported Earnings • Aug 09Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.56 loss in 2Q 2021)Second quarter 2022 results: US$0.44 loss per share (up from US$0.56 loss in 2Q 2021). Revenue: US$11.8m (up US$9.95m from 2Q 2021). Net loss: US$31.7m (loss narrowed 19% from 2Q 2021). Over the next year, revenue is forecast to grow 264%, compared to a 24% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 102% per year, which means it is well ahead of earnings.
Reported Earnings • May 06First quarter 2022 earnings released: US$0.55 loss per share (vs US$0.43 loss in 1Q 2021)First quarter 2022 results: US$0.55 loss per share (down from US$0.43 loss in 1Q 2021). Revenue: US$5.46m (down 47% from 1Q 2021). Net loss: US$38.6m (loss widened 30% from 1Q 2021). Over the next year, revenue is forecast to grow 317%, compared to a 28% growth forecast for the industry in Germany.
Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Executive VP, Chief Financial & Administrative Officer, Secretary and Director Susan Kanaya was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Apr 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Executive VP, Chief Financial & Administrative Officer, Secretary and Director Susan Kanaya was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 03Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: US$1.89 loss per share (down from US$0.84 loss in FY 2020). Revenue: US$32.2m (down 50% from FY 2020). Net loss: US$131.8m (loss widened 138% from FY 2020). Revenue missed analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 189%, compared to a 64% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 8 analysts covering ChemoCentryx expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$157.3m in 2024. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.35 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$17.7m (up 249% from 3Q 2020). Net loss: US$22.3m (loss narrowed 7.3% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 62% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 11Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.32 profit in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: US$1.81m (down 96% from 2Q 2020). Net loss: US$39.2m (down 294% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
Recent Insider Transactions • May 11Executive VP & COO recently bought €99k worth of stockOn the 7th of May, Tausif Butt bought around 11k shares on-market at roughly €9.10 per share. This was the largest purchase by an insider in the last 3 months. This was Tausif's only on-market trade for the last 12 months.
Reported Earnings • May 02First quarter 2021 earnings released: US$0.43 loss per share (vs US$0.35 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$10.4m (up 72% from 1Q 2020). Net loss: US$29.7m (loss widened 37% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 59% per year, which means it is well ahead of earnings.
Recent Insider Transactions • Mar 13Director recently sold €1.5m worth of stockOn the 5th of March, Geoffrey Parker sold around 32k shares on-market at roughly €47.52 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €4.8m more than they bought in the last 12 months.
Reported Earnings • Mar 02Full year 2020 earnings released: US$0.84 loss per share (vs US$0.97 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses were not reduced. Full year 2020 results: Revenue: US$64.9m (up 80% from FY 2019). Net loss: US$55.4m (flat on FY 2019). Over the last 3 years on average, earnings per share has fallen by 65% per year but the company’s share price has increased by 86% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Mar 02Revenue misses expectationsRevenue missed analyst estimates by 5.6%. Over the next year, revenue is expected to shrink by 19% compared to a 55% growth forecast for the Biotechs industry in Germany.
Is New 90 Day High Low • Feb 06New 90-day high: €54.18The company is up 20% from its price of €45.32 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €86.28 per share.
Recent Insider Transactions • Feb 05Independent Director recently sold €1.0m worth of stockOn the 2nd of February, Thomas Edwards sold around 20k shares on-market at roughly €50.67 per share. In the last 3 months, they made an even bigger sale worth €1.3m. Insiders have been net sellers, collectively disposing of €3.3m more than they bought in the last 12 months.
Recent Insider Transactions • Dec 30Independent Director recently sold €1.3m worth of stockOn the 28th of December, Thomas Edwards sold around 25k shares on-market at roughly €50.19 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.3m more than they bought in the last 12 months.
Is New 90 Day High Low • Dec 15New 90-day high: €49.12The company is up 12% from its price of €43.92 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €76.07 per share.
Is New 90 Day High Low • Dec 10New 90-day high: €47.85The company is up 12% from its price of €42.71 on 03 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €70.28 per share.
Is New 90 Day High Low • Nov 20New 90-day high: €47.06The company is up 4.0% from its price of €45.15 on 21 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €68.44 per share.
Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.35 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$5.09m (down 52% from 3Q 2019). Net loss: US$24.1m (loss widened 87% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 96% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Nov 11Revenue misses expectationsRevenue missed analyst estimates by 53%. Over the next year, revenue is expected to shrink by 6.9% compared to a 309% growth forecast for the Biotechs industry in Germany.
お知らせ • Oct 29ChemoCentryx, Inc. Announces Positive Topline Results of Phase II Aurora Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)ChemoCentryx, Inc. announced positive topline data from the company’s AURORA randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial of avacopan for the treatment of the chronic disabling skin disease Hidradenitis Suppurativa (HS). Avacopan is a first-in-class, orally-administered selective inhibitor of the complement C5a receptor. The Phase II AURORA clinical trial randomized 398 patients to one of three treatment arms. The study population included patients with moderate HS (Hurley Stage II) or severe HS (Hurley Stage III), which were stratified evenly across the treatment groups. The primary endpoint of the proportion of all patients (both moderate Hurley Stage II plus severe Hurley Stage III) achieving Hidradenitis Suppurativa Clinical Response (HiSCR), as assessed 10 mg twice-daily (BID) and 30 mg BID dosing regimens of avacopan against placebo after 12 weeks of treatment in the combined study population, was not achieved with statistical significance at either dose level, although a numerical improvement was noted at the 30mg BID dose. Importantly, avacopan 30mg BID demonstrated a statistically significant higher response than placebo in the pre-specified population of Hurley Stage III (severe) HS patients in the study. The Company plans to advance avacopan into Phase III development for the treatment of severe HS. A consistency of effect with avacopan was noted in Hurley Stage III patients across every secondary endpoint assessed to date. Favorable reductions for avacopan were observed in International HS Severity Score (IHS4), as well as reduction in AN (abscesses and inflammatory nodules), draining fistula, and abscess count at week 12 (all % change from baseline to week 12), relative to placebo. Avacopan demonstrated a favorable safety profile. Treatment emergent adverse events (TEAEs) of all types were observed to be fewer in the avacopan groups (48.5%) than with placebo (55%). The majority of TEAEs were related to underlying HS and were mild to moderate. Serious TEAEs were observed in 2.3% of placebo patients vs. 1.5% on avacopan.
お知らせ • Sep 18ChemoCentryx, Inc. Announces FDA Acceptance of the Avacopan New Drug Application for the Treatment of ANCA-Associated VasculitisChemoCentryx, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for avacopan, an orally-administered selective complement 5a receptor inhibitor, for the treatment of ANCA-Associated Vasculitis and has set July 7, 2021 as the Prescription Drug User Fee Act (PDUFA) goal date for the avacopan NDA. Avacopan is a first-in-class, orally administered therapy that employs a novel, highly targeted mode of action in the treatment of ANCA-associated vasculitis. In its NDA acceptance letter, the FDA also indicated that it may, but has not yet determined whether to hold an advisory committee meeting to discuss the application per guidelines for new molecular entities. The NDA included data from the global, Phase III ADVOCATE trial, which demonstrated statistical superiority in sustaining remission at 52 weeks in the avacopan group compared to the prednisone group. In the trial, the avacopan group also showed significantly lower glucocorticoid toxicity, greater improvement in kidney function and greater improvement in health-related quality of life measures compared to the prednisone group. Finally, avacopan demonstrated favorable safety results, with fewer patients having serious adverse events in the avacopan group than in the prednisone group. ADVOCATE and ANCA-Associated Vasculitis: The ADVOCATE trial of avacopan was a global, randomized, double-blind, active-controlled, double-dummy Phase III trial of 331 patients with ANCA-associated vasculitis in 20 countries. Eligible study subjects were randomized to receive avacopan plus either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate) or prednisone plus either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate). ANCA-associated vasculitis is a systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. This results in organ damage and failure, with the kidney as the major target, and is fatal if not treated. Currently, treatment for ANCA-associated vasculitis consists of courses of non-specific immuno-suppressants (cyclophosphamide or rituximab), combined with the administration of daily glucocorticoids (steroids) for prolonged periods of time, which can be associated with significant clinical risk including death from infection. Avacopan is a first-in-class, orally-administered small molecule that employs a novel, highly targeted mode of action in the treatment of ANCA-associated vasculitis and other complement-driven autoimmune and inflammatory diseases. By precisely blocking the receptor (the C5aR) for the pro-inflammatory complement system fragment known as C5a on destructive inflammatory cells such as blood neutrophils, avacopan arrests the ability of those cells to do damage in response to C5a activation, which is known to be the driver of ANCA-associated vasculitis. Current therapies for ANCA-associated vasculitis and other related illnesses typically include broad immunosuppression with daily doses of glucocorticoids (steroids) such as prednisone or methylprednisone, which can cause significant illness and even death. Avacopan therapy was designed to prevent these outcomes. Moreover, avacopan’s selective inhibition of only the C5aR leaves the beneficial C5a pathway through the C5L2 receptor functioning normally. ChemoCentryx is also developing avacopan for the treatment of patients with C3 glomerulopathy (C3G) and hidradenitis suppurativa (HS). The U.S. Food and Drug Administration has granted avacopan orphan drug designation for ANCA-associated vasculitis and C3G. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of ANCA-associated vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), as well as for C3G. ChemoCentryx is responsible for the discovery and development of avacopan and owns and retains the commercial rights to the drug in the United States. ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan in markets outside of the U.S.
お知らせ • Aug 04ChemoCentryx, Inc. to Report Q2, 2020 Results on Aug 10, 2020ChemoCentryx, Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 10, 2020
お知らせ • Jul 03ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from Russell Microcap IndexChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from Russell Microcap Index